Q-omics provides the consensus-scored SYNDIG1 profile across patient tissues and cancer cell-line models. SYNDIG1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SYNDIG1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SYNDIG1 RNA expression shows 19,108 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, HNSC, and GBM as cancer lineages where SYNDIG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNDIG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNDIG1 survival associations across molecular data types. SYNDIG1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNDIG1 RNA expression–survival associations across cancer types. High SYNDIG1 expression shows unfavorable associations in THCA, CESC, BLCA and ACC, but favorable associations in BRCA and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for SYNDIG1 RNA expression.
This table summarizes SYNDIG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SYNDIG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNDIG1 shows lower tumor expression in THCA, KIRP and KICH and higher tumor expression in HNSC, LUAD and COAD. The HNSC box plot shows higher SYNDIG1 RNA expression in tumor versus normal tissue (log2 FC = +1.101, t-test p < 0.001).
This table shows molecular features associated with SYNDIG1 in patient tissues and cancer cell lines. In patient samples, SYNDIG1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNDIG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
